PT - JOURNAL ARTICLE AU - Antoine Beurnier AU - Youri Yordanov AU - Agnès Dechartres AU - Aurélien Dinh AU - Erwan Debuc AU - François-Xavier Lescure AU - Patrick Jourdain AU - Luc Jaulmes AU - Marc Humbert TI - Characteristics and outcomes of asthmatic outpatients with COVID-19 who receive home telesurveillance AID - 10.1183/23120541.00012-2022 DP - 2022 Jan 01 TA - ERJ Open Research PG - 00012-2022 4099 - http://openres.ersjournals.com/content/early/2022/07/28/23120541.00012-2022.short 4100 - http://openres.ersjournals.com/content/early/2022/07/28/23120541.00012-2022.full AB - Background The prognosis of asthmatic outpatients with COVID-19 needs to be clarified. The objectives of this study were 1) to investigate the characteristics and outcomes of asthmatics receiving initial ambulatory care and home monitoring for COVID-19 with Covidom, a telesurveillance solution and 2) to compare the characteristics and outcomes between asthmatics and non-asthmatics.Methods Inclusion criteria were age ≥18 years, suspected or confirmed COVID-19 diagnosis allowing initial ambulatory care, registration in Covidom between March 2020 and April 2021, completion of the initial medical questionnaire. We compared clinical characteristics and outcomes between asthmatics and non-asthmatics and we evaluated whether asthma was independently associated with clinical worsening (hospitalisation or death) within 30 days follow-up using a multivariate logistic regression model.Results 33 815 patients met the inclusion criteria. Asthma was reported in 4276 (12.6%). The main comorbidities among asthmatics were obesity (23.1%), hypertension (12.7%) and diabetes (4.5%). As compared with non-asthmatics, asthmatics were more often female (70.0 versus 62.1%, p<0.001), of younger age (42.2 versus 43.8 years, p<0.001) and obese (23.1 versus 17.6%, p<0.001). The rate of hospitalisation did not differ significantly (4.7 versus 4.2%, p=0.203) and no asthmatic patient died during follow-up (versus 25 non-asthmatics, 0.1%; p=0.109). In multivariate analysis, asthma was independently associated with higher risk of clinical worsening (OR=1.23 (1.04–1.44), p=0.013).Conclusion In a large French cohort of patients receiving initial ambulatory care and home monitoring for COVID-19, asthma was independently associated with higher risk of clinical worsening although no asthmatic patient died within the 30 days follow-up.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. Beurnier reports personal fees from AstraZeneca, personal fees from Sanofi outside the submitted work.Conflict of interest: Youri Yordanov have nothing to disclose.Conflict of interest: Agnès Dechartres have nothing to disclose.Conflict of interest: Aurélien Dinh have nothing to disclose.Conflict of interest: Erwan Debuc have nothing to disclose.Conflict of interest: François-Xavier Lescure have nothing to disclose.Conflict of interest: Patrick Jourdain have nothing to disclose.Conflict of interest: Luc Jaulmes have nothing to disclose.Conflict of interest: Pr. Humbert reports personal fees and non-financial support from GlaxoSmithKline, personal fees from Astrazeneca, personal fees from Novartis, personal fees from Sanofi, personal fees from Chiesi, outside the submitted work.